非典型抗精神病药物对精神分裂症患者血清胶质源性神经营养因子水平的影响

Effect of atypical antipsychotics on glial cell line-derived neurotrophic factor levels in schizophrenia patients

目的探讨非典型抗精神病药物治疗对血清胶质源性神经营养因子(GDNF)水平的影响。方法选取104例未服药精神分裂症患者和70名健康对照者。所有患者均单一服用非典型抗精神病药物,分别在基线和2、4、6、8周对患者的血清GDNF水平和精神症状进行评估。结果患者基线血清GDNF浓度显著低于正常组(t=5.596,P<0.001),经抗精神病药物治疗后,GDNF浓度逐渐增加伴有精神症状显著改善(P<0.01)。药物治疗有效的患者在治疗前后GDNF水平发生显著改变(P<0.01),而无效组患者的GDNF水平无显著变化(P>0.05)。治疗前后GDNF变化水平和患者病程显著负相关(r=-0.270,P=0.024)。结论 GDNF可能参与精神分裂症的发病机制和药物疗效的作用机制。

ObjectiveTo study effect of atypical antipsychotics on glial cell line derived neurotrophic factor （GDNF） levels in schizophrenia patients. Methods A total of 104 drug free schizophrenic patients and 70 healthy controls were recruited. All patients were treated with atypical antipsychotic monotherapy. GDNF serumlevels and psychiatric symptoms were assessed at baseline and at 2, 4, 6 and 8 weeks of treatment. ResultsBaseline serum GDNF levels were significantly lower in schizophrenic patients than healthy controls （t=5.596, P〈0.001）. GDNF levels gradually increased accompanied by a reduction in psychiatric symptoms during antipsychotic therapy （P〈0.01）. The levels of GDNF in responders were significantly changed after treatment （P〈0.01）, however, no significant change was found in non responders （P〉0.05）. Furthermore, a negative association between GDNF levels after pharmacotherapy and disease duration in schizophrenic subjects could be observed （r=-0.270, P=0.024）. ConclusionThe present study suggests that GDNF may be involved in the mechanisms of schizophrenia pathogenesis and pharmacological efficacy.